AbbVie reports trial results. AbbVie stock trades 0.10 percent above EUR 254.40
Published on 10/24/2026 at 10:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTrial update and trading price
- On October 22, 2026, AbbVie reported a 31.4 percent HiSCR75 response rate for lutikizumab versus 23.4 percent for placebo.
- AbbVie stock trades in weekend trading at Lang & Schwarz at EUR 254.65 at 10:45 a.m. CEST on October 24, 2026, 0.10 percent above the Xetra close of October 23, 2026.
- The next Xetra session is scheduled for October 26, 2026.
AbbVie reported positive topline results from the Phase 3 INTREPID trial on October 22, 2026, according to an AbbVie release distributed by PR Newswire. The company said investigational lutikizumab achieved the primary endpoint in adults and adolescents with moderate to severe hidradenitis suppurativa.
Market context: Market report S&P 500.
The week in figures
At 10:45 a.m. CEST on October 24, 2026, AbbVie stock traded in weekend trading at Lang & Schwarz at EUR 254.65. That was 0.10 percent above the Xetra close of October 23, 2026, at EUR 254.40. The quote was recorded while Xetra and the primary exchanges were closed.
The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of AbbVie stock.
Chronology of the week
On October 22, 2026, AbbVie said the INTREPID study met its primary endpoint and eight ranked secondary endpoints. At Week 16, the HiSCR75 response rate was 31.4 percent for lutikizumab versus 23.4 percent for placebo, with a reported p-value of 0.001 or lower. At Week 8, 26.2 percent of lutikizumab patients achieved NRS3 versus 15.0 percent of placebo patients.
The company also reported that 18.4 percent of patients receiving lutikizumab experienced a disease flare during the first 16 weeks, compared with 28.1 percent in the placebo group. AbbVie said the treatment was generally well tolerated, with no new safety concerns identified. The release said additional INTREPID data are expected in 2027.
Dates of the coming week
The next Xetra session is scheduled for October 26, 2026. AbbVie has scheduled its third-quarter 2026 financial results for October 30, 2026, before the market opens, according to the company topic page.
